2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- manufacturers
- JNJ-61803534
-
- $1980.00 / 50mg
-
2025-04-28
- CAS:1917306-14-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- Basic information |
| Product Name: | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- | | Synonyms: | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]-;4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate;tert-butyl (3R;5-[2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[(2R)-2-methylpyrrolidine-1-carbonyl]-1,3-thiazole-2-carboxamide | | CAS: | 1917306-14-9 | | MF: | C23H23Cl2F6N3O4S | | MW: | 622.41 | | EINECS: | | | Product Categories: | | | Mol File: | 1917306-14-9.mol | ![2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- Structure](CAS/20210305/GIF/1917306-14-9.gif) |
| | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- Chemical Properties |
| density | 1.494±0.06 g/cm3(Predicted) | | pka | 4.85±0.46(Predicted) | | form | Solid | | color | White to off-white |
| | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- Usage And Synthesis |
| Description | JNJ-61803534 is a novel potent RORγt inverse agonist, selectively inhibiting RORγt-driven transcription versus closely-related family members, RORα and RORβ, also inhibiting IL-17A production in human CD4+ T cells under Th17 differentiation conditions, but not inhibiting IFNγ production under Th1 differentiation conditions, and having neither impact on in vitro differentiation of regulatory T cells (Treg), nor on the suppressive activity of natural Tregs. | | Uses | JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6? nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions[1]. | | in vivo | JNJ-61803534 (100 mg/kg, p.o.) inhibits ex vivo stimulated IL-17A production in the blood of mice[1].
JNJ-61803534 (3-100 mg/kg BID or 60 mg/kg QD, p.o.) alleviates inflammation, cartilage damage, bone destruction in mouse collagen-induced arthritis (CIA) model[1].
JNJ-61803534 (30 and 100 mg/kg, p.o.) alleviates Imiquimod (HY-B0180)-induced dermal psoriatic-like inflammation in mice[1].
| Animal Model: | Mouse collagen-induced arthritis (CIA) model[1] | | Dosage: | 3-100 mg/kg BID or 60 mg/kg QD | | Administration: | Oral administration (p.o.) | | Result: | Decreased clinical arthritis scores and hind paw histopathology scores. |
| | IC 50 | RORγt | | References | [1] Xue X, et al. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534. Sci Rep. 2021 May 26;11(1):11066. DOI:10.1038/s41598-021-90497-9 |
| | 2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- Preparation Products And Raw materials |
|